生物技术
生产(经济)
商业化
保健品
生物
范围(计算机科学)
业务
食品科学
营销
计算机科学
宏观经济学
经济
程序设计语言
作者
Dileep Sai Kumar Palur,Shannon R Pressley,Shota Atsumi
出处
期刊:Molecules
[MDPI AG]
日期:2023-02-03
卷期号:28 (3): 1491-1491
被引量:21
标识
DOI:10.3390/molecules28031491
摘要
Human milk oligosaccharides (HMOs) are complex nonnutritive sugars present in human milk. These sugars possess prebiotic, immunomodulatory, and antagonistic properties towards pathogens and therefore are important for the health and well-being of newborn babies. Lower prevalence of breastfeeding around the globe, rising popularity of nutraceuticals, and low availability of HMOs have inspired efforts to develop economically feasible and efficient industrial-scale production platforms for HMOs. Recent progress in synthetic biology and metabolic engineering tools has enabled microbial systems to be a production system of HMOs. In this regard, the model organism Escherichia coli has emerged as the preferred production platform. Herein, we summarize the remarkable progress in the microbial production of HMOs and discuss the challenges and future opportunities in unraveling the scope of production of complex HMOs. We focus on the microbial production of five HMOs that have been approved for their commercialization.
科研通智能强力驱动
Strongly Powered by AbleSci AI